The value of parathyroid hormone determination in ultrasound-guided fine-needle aspirates (FNA-PTH) for preoperative localization of parathyroid lesions.

2014 ◽  
Author(s):  
Magdalena Kochman ◽  
Waldemar Misiorowski ◽  
Lucyna Papierska ◽  
Elzbieta Stachlewska-Nasfeter ◽  
Witold Chudzinski ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Preoperative Localization ◽  
Ultrasound Guided ◽  
Fine Needle ◽  
Fine Needle Aspirates ◽  
Parathyroid Lesions

scholarly journals Thyroid haemangiosarcoma in a seven-year-old female Shih Tzu

2020 ◽  
Vol 8 (2) ◽  
pp. e001012
Author(s):  
Luis Pedro Rocha Moreira ◽  
Emma Scurrell ◽  
Paul Mahoney ◽  
Stephen Baines
Keyword(s):  
Histopathological Examination ◽  
Abdominal Ultrasound ◽  
Neck Mass ◽  
Clinical Staging ◽  
Ultrasound Guided ◽  
Fine Needle ◽  
Fine Needle Aspirates ◽  
History Of ◽  
The Right ◽  
Mixed Tumours

Canine thyroid tumours are uncommon and the majority of tumours are carcinomas or adenomas, with only very few mixed tumours or metastases from distant sites described to date. A primary thyroid haemangiosarcoma has never been reported in veterinary medicine. In this case report, we describe a dog with a history of a large, non-painful, mobile ventral neck mass in the right paralaryngeal region. CT and ultrasound-guided fine needle aspirates were used for clinical staging. The mass was surgically excised and histopathological examination indicated a haemangiosarcoma. Abdominal ultrasound revealed the presence of splenic nodules and splenectomy indicated the presence of haemangiosarcoma. Chemotherapy with doxorubicin was started, but the dog was euthanased after three rounds of therapy, 97 days after the mass was discovered.

Increased diagnostic yield of endoscopic ultrasound-guided fine needle aspirates with flow cytometry and immunohistochemistry

2012 ◽  
Vol 41 (12) ◽  
pp. 1043-1051 ◽  
Author(s):  
Jamie B. Sodikoff ◽  
Hunter L. Johnson ◽  
Melinda M. Lewis ◽  
Sagar S. Garud ◽  
Sheila J. Bharmal ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Endoscopic Ultrasound ◽  
Diagnostic Yield ◽  
Ultrasound Guided ◽  
Fine Needle ◽  
Fine Needle Aspirates

Cytological diagnosis of cardiac masses with ultrasound guided fine needle aspirates

2016 ◽  
Vol 18 (1) ◽  
pp. 47-56 ◽  
Author(s):  
Brigite Pedro ◽  
Christopher Linney ◽  
Xavier Navarro-Cubas ◽  
Hannah Stephenson ◽  
Joanna Dukes-McEwan ◽  
...  
Keyword(s):  
Cytological Diagnosis ◽  
Ultrasound Guided ◽  
Fine Needle ◽  
Fine Needle Aspirates ◽  
Cardiac Masses

Rapid immunohistochemical analysis of pancreatic cytology from endoscopic ultrasound-guided fine-needle aspirates: A prospective clinical trial.

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 400-400
Author(s):  
Susan Tsai ◽  
Paul S. Ritch ◽  
Beth Erickson ◽  
Ben George ◽  
Fabian McCartney Johnston ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Clinical Trial ◽  
Endoscopic Ultrasound ◽  
Molecular Techniques ◽  
Prospective Clinical Trial ◽  
Molecular Profile ◽  
Ultrasound Guided ◽  
Borderline Resectable ◽  
Fine Needle ◽  
Fine Needle Aspirates

400 Background: Acquisition of pancreatic cancer (PC) tissue specimens from endoscopic ultrasound-guided fine needle aspirates (EUS-FNA) is crucial to investigational pancreatic cancer trials seeking to utilize molecular profile directed therapy. Methods: In an ongoing prospective clinical trial we have utilized molecular profiling of EUS-FNA specimens from patients with resectable and borderline resectable pancreatic cancers. Cytologic specimens were evaluated for six biomarkers to guide the choice of neoadjuvant therapy: secreted protein acid rich in cysteine (SPARC), thymidylate synthase (TYMS), ribonucleotide reductase M1 (RRM1), human equilibrative nucleoside transporter 1 (ENT1), excision repair cross-complementing 1 (ERCC), and topoisomerase 1 (TOPO). Final immunohistochemical (IHC) interpretation was scored by a single pathologist using both staining intensity and percent immunochemically reactive cells. Results: The trial has enrolled 99 patients to date; 47 (47%) resectable patients and 52 (52%) borderline resectable patients. No patient experienced a EUS-FNA related complication. IHC profiling was reported in a median of 5 business days (IQR:3). Of the 99 patient samples, 73 (74%) had adequate cellularity for IHC profiling and this was not affected by stage of disease (n = 35, resectable; n = 38 borderline resectable; p = 0.82). Analysis of SPARC expression was limited to specimens with adequate stromal cells for analysis (n = 50, 51%). Among the 73 patients with adequate tissue for profiling, expression profiling was interpreted to be favorable for the following therapeutic agents: nab-paclitaxel, (SPARC, n = 35, 48%), 5-fluorouracil (TYMS, n = 68, 93%), gemcitabine (RRM1, n = 34, 47%; ENT1, n = 38, 52%), platinum agents (ERCC, n = 30, 41%), and irinotecan (TOPO, n = 62, 85%). Conclusions: The use of EUS-FNA specimens for molecular diagnostics is feasible and IHC analysis was possible in 74% of patient specimens, with preservation of stromal components in over 50%. Further refinement of molecular techniques may expand the breadth of analysis which may be performed, to include quantitative polymerase chain reaction and genetic sequencing Clinical trial information: NCIT01726582.

Sign in / Sign up

Export Citation Format

Share Document